Table 2.
IC50 [μM] and MC50 [μg mL−1] values of cisplatin, 1−3, free ligands, SBA-15, and SBA-15|1−SBA-15|3 determined with CV and MTT assays (72 h).
| Compound/Material | CV | MTT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-468 | HCC1937 | MCF-7 | BT-474 | 4T1 | MDA-MB-468 | HCC1937 | MCF-7 | BT-474 | 4T1 | |
| IC50 [µM] | IC50 [µM] | |||||||||
| Acetyl-protected caffeic acid | >100 | >100 | ||||||||
| Acetyl-protected ferulic acid | >100 | >100 | ||||||||
| Ferulic acid | >100 | >100 | ||||||||
| Cisplatin | 3.3 ± 0.2 | 7.6 ± 0.9 | 33.6 ± 4.8 | 54.9 ± 6.0 | 3.2 ± 0.3 | 0.6 ± 0.1 | 4.3 ± 0.7 | 32.0 ± 4.3 | 70.3 ± 8.5 | 1.3 ± 0.1 |
| Cisplatin-acetyl protected caffeate conjugate (1) | 2.6 ± 0.7 | 8.9 ± 0.3 | 16.0 ± 2.3 | 5.4 ± 0.3 | 4.4 ± 0.7 | 2.7 ± 0.8 | 9.9 ± 0.5 | > 50 | 4.5 ± 0.4 | 3.3 ± 0.4 |
| Cisplatin-acetyl protected ferulate conjugate (2) | 3.5 ± 0.5 | 10.4 ± 1.1 | 8.4 ± 2.2 | 5.9 ± 0.4 | 3.8 ± 0.8 | 5.5 ± 4.3 | 27.6 ± 2.6 | 9.7 ± 1.2 | ||
| Cisplatin-ferulate conjugate (3) | 7.1 ± 0.3 | 11.1 ± 0.8 | 19.9 ± 1.3 | >50 | 8.3 ± 0.7 | 15.1 ± 2.1 | >50 | >50 | ||
| SBA-15|1 (a) | 0.3 ± 0.03 | 1.7 ± 0.1 | 1.6 ± 0.1 | 0.0001 ± 0.00001 | 1.0 ± 0.2 | 0.1 ± 0.001 | 0.3 ± 0.02 | 0.3 ± 0.1 | 0.1 ± 0.001 | 0.8 ± 0.04 |
| SBA-15|2 (a) | 0.1 ± 0.01 | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.0017 ± 0.0001 | 0.02 ± 0.002 | 0.2 ± 0.02 | / | 0.1 ± 0.02 | ||
| SBA-15|3 (a) | 1.6 ± 0.1 | 2.6 ± 0.5 | 4.4 ± 0.5 | 0.7 ± 0.1 | 0.4 ± 0.01 | 1.0 ± 0.2 | 3.7 ± 0.2 | 1.3 ± 0.2 | ||
| MC50 [µg mL−1] | MC50 [µg mL−1] | |||||||||
| SBA-15 | >100 | >100 | ||||||||
| SBA-15|1 | 3.0 ± 0.5 | 19.9 ± 1.0 | 18.5 ± 1.0 | 0.0017 ± 0.0002 | 11.9 ± 1.9 | 0.6 ± 0.02 | 3.3 ± 0.3 | 7.3 ± 0.8 | 0.7 ± 0.02 | 9.7 ± 0.5 |
| SBA-15|2 | 3.6 ± 0.4 | 32.9 ± 2.1 | 35.0 ± 3.0 | 0.6 ± 0.006 | 0.6 ± 0.1 | 6.5 ± 0.7 | >50 | 4.3 ± 0.7 | ||
| SBA-15|3 | 3.9 ± 0.2 | 6.4 ± 1.2 | 10.7 ± 1.3 | 1.7 ± 0.3 | 1.1 ± 0.03 | 2.3 ± 0.4 | 5.0 ± 0.5 | 3.3 ± 0.6 | ||
(a) recalculated based on platinum content (EDX) and drug release (ICP-OES).